Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2022
2021
2020
Profitability Metrics
Gross Margin
73.34%
Operating Margin
92.20%
Net Margin
80.89%
Efficiency Metrics
Revenue per Expense Ratio
12.82
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
92.20%
Income Tax Rate
0.00%
EPS
1.1200000000
Balance Sheet Analysis
Current Ratio
29.51
Cash Ratio
17.75
Working Capital
$69.02M
Debt to Equity
0.17
Debt to Assets
11.17%
Equity Ratio
66.88%
Cash Flow Analysis
Operating Cash Flow Ratio
-42.59%
Free Cash Flow Ratio
-42.59%
CapEx to Revenue
0.00%
Dividends Paid
$166.60M
Stock Buybacks
No buybacks
Total Shareholder Returns
$166.60M
Cash Position Change
97.67%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Detailed Growth Metrics
Core Performance
Revenue
283.45%
Net Income
237.26%
EPS
198.25%
Operating Income
256.44%
Operational Efficiency
R&D Expenses
0.00%
SG&A Expenses
19.74%
Operating Cash Flow
-35.20%
Free Cash Flow
-35.20%
Balance Sheet Health
Assets
31.05%
Debt
0.53%
Book Value per Share
5.68%
Inventory
0.00%
Shareholder Returns
Dividends per Share
-2.68%
Shares Outstanding
39.71%
Long Term Trends
3Y Revenue/Share
-56.42%
5Y Revenue/Share
406.71%
3Y Dividend/Share
-2.41%
5Y Dividend/Share
-39.80%